P. Fumoleau

发表

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.

J. Wanders, E. Raymond, J. Schellens, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

David Miles, Shailendra Verma, Chris Twelves, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Alexandre Cochet, Olivier Humbert, Salim Kanoun, 2015, Clinical Cancer Research.

Identification of molecular apocrine breast tumours by microarray analysis

David Cameron, Mauro Delorenzi, Jonas Bergh, 2005, Oncogene.

Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?

Franck Bonnetain, Maryse Fiche, William Jacot, 2014, Critical reviews in oncology/hematology.

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.

J. Bonneterre, A. Monnier, I. van Praagh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer.

A. Ravaud, J. Wanders, N. Pavlidis, 2003, European journal of cancer.

Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

J. Wanders, E. Raymond, J. Beijnen, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population P harmacokinetics o f t he N ovel A nticancer Agent E 7070 D uring F our P hase I S tudies: M odel B uilding and V alidation

J. Wanders, C. Punt, E. Raymond, 2002 .

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam

J. Wanders, C. Punt, E. Raymond, 2005, Investigational New Drugs.

Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial

M. Namer, J. Bonneterre, A. Monnier, 2007, British Journal of Cancer.

Taxanes in adjuvant breast cancer setting: which standard in Europe?

M. Campone, P. Fumoleau, P. Kerbrat, 2005, Critical reviews in oncology/hematology.

Reproducibility of image interpretation in immunoscintigraphy performed with indium-111- and iodine-131-labeled OC125 F(ab')2 antibody injected into the same patients.

P. Fumoleau, J. Chatal, F. Dubois, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comparison of the Pharmacokinetics of S-1, an Oral Anticancer Agent, in Western and Japanese Patients

Emmanuelle Comets, Yusuke Tanigawara, J. Wanders, 2003, Journal of Pharmacokinetics and Pharmacodynamics.

Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma

P. Reichardt, P. Fumoleau, J. Blum, 2003, Cancer.

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

L. Chow, A. Wolff, A. Berkenblit, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of serial carcinoembryonic antigen assays in detecting relapses in breast cancer involving high risk of metastasis.

P. Fumoleau, G. Ricolleau, J. Chatal, 1981, European journal of cancer.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

T. Delozier, J. Bonneterre, B. Asselain, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Impact of Taxotere on Adjuvant Breast Cancer

P. Fumoleau, H. Roché, 2005 .

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.

M. Namer, J. Bonneterre, A. Monnier, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of vinorelbine in patients with androgen-independent prostate cancer.

M. Piccart, D. Chopin, Y. Humblet, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088.

H. Rugo, J. Sparano, M. Campone, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of E 7070 in patients with metastatic melanoma

M. Gore, S. Aamdal, F. Caponigro, 2004 .

Phase II study of E7070 in patients with metastatic melanoma.

M. Gore, S. Aamdal, F. Caponigro, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).

C. Punt, M. Campone, M. Ravic, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene

W. Eiermann, D. Slamon, D. Toppmeyer, 2001 .

Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.

D. Lacombe, M. Borner, P. Fumoleau, 2004, European journal of cancer.

Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study.

P. Viens, P. Fumoleau, P. Marino, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.

J. Albanell, M. Campone, P. Fumoleau, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

J. Wanders, P. Fumoleau, J. Schellens, 2017 .

Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer.

D. Lacombe, F. Caponigro, P. Fumoleau, 2002, European journal of cancer.

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

J. Wanders, J. Schellens, V. Grünwald, 2003, European journal of cancer.

Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group.

P. Fumoleau, P. Fargeot, P. Kerbrat, 1996, European journal of cancer.

Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases

M. Namer, C. Jacquillat, D. Khayat, 1990, Cancer.

Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer

J. Bonneterre, M. Campone, S. Urien, 2003, Cancer Chemotherapy and Pharmacology.

The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors

G. Peters, G. Giaccone, J. Schellens, 2004, Clinical Cancer Research.

Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors

G. Peters, G. Giaccone, J. Wanders, 2003, Cancer Chemotherapy and Pharmacology.

HER2‐positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable

P. Arveux, P. Fumoleau, A. Bertaut, 2017, European journal of cancer care.

A. Buzdar, D. Finkelstein, P. Goss, 2015, European journal of cancer.

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

W. Gradishar, A. Buzdar, D. Finkelstein, 2013, The Lancet. Oncology.

Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breast carcinomas: Relation to morphology, cell proliferation and expression of breast cancer‐related genes

B. Dutrillaux, H. Avet-Loiseau, P. Fumoleau, 2000, International journal of cancer.

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.

T. Delozier, M. Namer, A. Monnier, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme.

M. J. van den Bent, D. Lacombe, M. Campone, 2002, Annals of Oncology.

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours

P. Fumoleau, N. Isambert, V. Trillet-lenoir, 2012, British Journal of Cancer.

Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

P. Fumoleau, N. Isambert, V. Trillet-lenoir, 2012, Clinical Cancer Research.

Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.

M. Campone, P. Loadman, P. Fumoleau, 2010, European journal of cancer.

Current status of Taxotere® (docetaxel) as a new treatment in breast cancer

M. Glabbeke, P. Fumoleau, V. Diéras, 2004, Breast Cancer Research and Treatment.

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

S. Culine, M. Namer, P. Fumoleau, 2004, European journal of cancer.

Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group.

E. D. de Vries, J. Wanders, P. Fumoleau, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.

G. Giaccone, D. Lacombe, E. Smit, 2004, European Journal of Cancer.

Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study.

M. J. van den Bent, D. Lacombe, E. Raymond, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

M. Campone, P. Fumoleau, V. Diéras, 2016, Oncology and Therapy.

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

P. Fumoleau, C. Hill, P. Fargeot, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study

R. Stupp, A. Brandes, D. Lacombe, 2005 .

Taxoids in combination chemotherapy for metastatic breast cancer

P. Fumoleau, V. Diéras, J. Misset, 1996, Anti-cancer drugs.

Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.

A. Schneeweiss, R. Kreienberg, J. Mayordomo, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Cardiac dysfunction induced by trastuzumab].

M. Campone, P. Fumoleau, E. Bourbouloux, 2004, Bulletin du Cancer.

Proven bioequivalence of blood exposure between vinorelbine 80 mg/m2 oral and 30 mg/m2 IV doses in cancer patients

R. Stupp, L. Nguyen, P. Fumoleau, 2005 .

A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.

P. Rouanet, P. Fumoleau, J. Chatal, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas.

P. Fumoleau, J. Chatal, C. Curtet, 1989, Cancer research.

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

B. Chauffert, P. Fumoleau, F. Ghiringhelli, 2008, Clinical Cancer Research.

CHAPTER 26 – SUPERIORITY OF AVCF (ADRIAMYCIN, VINCRISTINE, CYCLOPHOSPHAMIDE, AND 5-FLUOROURACIL) OVER CMF (CYCLOPHOSPHAMIDE, METHOTREXATE, AND 5-FLUOROURACIL) AS ADJUVANT CHEMOTHERAPY FOR BREAST CANCER: A PHASE III TRIAL OF ASSOCIATION ONCOFRANCE

P. Fumoleau, G. Mathé, D. Belpomme, 1985 .

Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis

B. Chauffert, P. Fumoleau, P. Fargeot, 2006, Anti-cancer drugs.

New Vinca Alkaloids in Clinical Development

P. Fumoleau, S. Guiu, 2013, Current Breast Cancer Reports.

Docetaxel in combination with doxorubicin or vinorelbine.

P. Fumoleau, V. Diéras, J. Misset, 1997, European journal of cancer.

Immunoscintigraphy of colon carcinoma.

J. Douillard, P. Fumoleau, H. Koprowski, 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.

D. Lacombe, P. Bachmann, P. Fumoleau, 2003, European journal of cancer.

Changes in 18 F-FDG tumor metabolism after a ﬁ rst course of neoadjuvant chemotherapy in breast cancer: in ﬂ uence of tumor subtypes

P. Fumoleau, L. Arnould, A. Cochet, 2012 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer

M. Espié, M. Namer, P. Fumoleau, 2001, Oncology.

Pregnancy, fertility concerns, and fertility preservation procedures in French breast cancer survivors in the FEERIC national study (on behalf of the Seintinelles research network).

M. Espié, F. Reyal, B. Asselain, 2021, medRxiv.

Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.

J. Wanders, M. Ravic, P. Fumoleau, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of E 7070 , a Chloroindolyl-Sulfonamide Anticancer Agent , Administered on a Weekly Schedule to Patients with Solid Tumors

J. Wanders, M. Ravic, P. Fumoleau, 2003 .

Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E

J. Wanders, E. Raymond, A. Calvert, 2000 .

Immunoscintigraphy of recurrences of gynecologic carcinomas.

P. Fumoleau, J. Chatal, C. Curtet, 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.

P. Fumoleau, M. Marty, C. Puozzo, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Absolute bioavailability and pharmacokinetics (PK) of oral vinorelbine (VRL) in patients (pts) with solid tumors

P. Fumoleau, M. Marty, A. Adenis, 1997 .

The effects of food on the pharmacokinetic profile of oral vinorelbine

P. Fumoleau, G. Robinet, R. Bugat, 2002, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic (PK) Interactions between Lapatinib (L) and Vinorelbine (VNR) in a Phase I Study in Locally Advanced or Metastatic Breast Cancer (LAMBC) Patients(Pts) Overexpressing HER2. GEP-01 – A Study of the FNCLCC-Group of Early Phase Trials.

J. Bonneterre, P. Fumoleau, V. Diéras, 2009 .

Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen

T. Delozier, M. Namer, L. Mauriac, 2005, Breast Cancer Research and Treatment.

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.

A. Monnier, P. Fumoleau, E. Pujade-Lauraine, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.

G. Peters, A. Ravaud, D. Lacombe, 2005, European journal of cancer.

Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

D. Lacombe, L. Paz-Ares, A. V. van Oosterom, 2004, Investigational New Drugs.

Long-Term Gynecological Cancer Survivors in Côte d'Or: Health-Related Quality of Life and Living Conditions.

C. Coutant, P. Arveux, P. Fumoleau, 2019, The oncologist.

A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: preliminary results

P. Fumoleau, N. Isambert, P. Chevalier, 2008 .

Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today?

J. Bonneterre, P. Fumoleau, É. Luporsi, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial.

A. Ravaud, J. Wanders, M. Borner, 2001, European journal of cancer.

348 A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)

M. Piccart, A. Nichol, J. Bonneterre, 1995 .

Phase 2 Study of Single-Agent IV Vinflunine as Third-Line Treatment of Metastatic Breast Cancer After Failure of Anthracycline-/Taxane-Based Chemotherapy

M. Campone, M. Tubiana-Hulin, P. Fumoleau, 2009, American journal of clinical oncology.

Treatment beyond taxanes, emerging new cytotoxic agents

P. Fumoleau, 2009 .

Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.

P. Fumoleau, N. Isambert, E. Ferrant, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study

A. Schneeweiss, T. Delozier, A. Lluch, 2005 .

Future options in the treatment of ErbB2 (HER2)-positive breast cancer

P. Fumoleau, 2008 .

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

M. Campone, P. Fumoleau, N. Isambert, 2013, BMC Cancer.

Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?

P. Fumoleau, L. Arnould, B. Coudert, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel: a new active agent in the therapy of metastatic breast cancer.

P. Fumoleau, M. Trudeau, A. Seidman, 1997, Expert opinion on investigational drugs.

Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

L. Nguyen, I. Judson, P. Fumoleau, 2006, Investigational New Drugs.

Cancer Drug Development in Europe: A Selection of New Agents Under Development at the European Drug Development Network

D. Lacombe, P. Therasse, J. Verweij, 2003, Cancer Investigation.

Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy

K. Gelmon, J. Baselga, D. Miles, 2008 .

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach

P. Fumoleau, S. Ladoire, N. Isambert, 2022, Cancer Chemotherapy and Pharmacology.

The cycle-to-cycle variability of docetaxel pharmacokinetics (PK) assessed by population PK analysis

P. Fumoleau, M. Marty, R. Bruno, 1999 .

Gemcitabine combined with docetaxel in metastatic breast cancer.

P. Fumoleau, 2003, Seminars in oncology.

Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.

J. Bergh, M. Piccart, R. Coombes, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.

S. Schraub, M. Namer, J. Bonneterre, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors of contralateral breast cancer (CBC) in 3,653 early breast cancer (EBC) patients (pts): 9-year follow-up results of French Adjuvant Study Group (FASG) trials.

M. Namer, J. Bonneterre, A. Monnier, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Cystemustine, a New Nitrosourea, as Treatment of High-grade Brain Tumors in Adults

J. Madelmont, P. Fumoleau, P. Fargeot, 2000, Journal of Neuro-Oncology.

Inflammatory breast cancer outcome with epirubicin‐based induction and maintenance chemotherapy

P. Fumoleau, P. Fargeot, P. Kerbrat, 2006, Cancer.

European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.

R. Stupp, M. J. van den Bent, D. Lacombe, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.

J. Menten, R. Stupp, D. Lacombe, 2002, European journal of cancer.

Phase II study of XR 5000 ( DACA ) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme

D. Lacombe, M. Bent, M. Campone, 2002 .

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

K. Gelmon, M. Namer, J. Bonneterre, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Usefulness of imaging ovarian cancer recurrence with In-111-labeled monoclonal antibody (OC125) specific for CA125 antigen

P. Fumoleau, J. Chatal, J. Liehn, 1993 .

10-year follow-up update of French adjuvant study group 05 trial: FEC 100 regimen remains superior to FEC 50 in adjuvant chemotherapy of poor prognosis, node-positive, early breast cancer patients

M. Namer, J. Bonneterre, P. Fumoleau, 2003 .

Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.

S. Shak, F. Baehner, F. Penault-Llorca, 2014 .

Docetaxel combined with vinorelbine: phase I results and new study designs.

P. Fumoleau, G. Perrocheau, N. Azli, 1997, Oncology.

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

L B Sheiner, A Riva, P M Ravdin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.

B. Chauffert, P. Fumoleau, N. Isambert, 2008, Breast.

Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer

A. Manikhas, P. Fumoleau, A. Lundberg, 2008 .

Evaluation of the safety of C-1311 administered in a phase I dose-escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumors.

M. Campone, P. Loadman, P. Fumoleau, 2006, Journal of Clinical Oncology.

Preliminary results of a phase II study to evaluate gefitinib (ZD1839) combined with paclitaxel (P) and carboplatin (C) as second-line therapy in patients (pts) with ovarian carcinoma (OC)

T. Petit, F. Ringeisen, P. Fumoleau, 2004 .

Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer

J. Bonneterre, M. Campone, S. Urien, 2004, Cancer Chemotherapy and Pharmacology.

Impact of symptoms and toxicity on quality of life: Exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer.

A. Schneeweiss, S. Chan, G. Romieu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long median survival with capecitabine (X) single-agent therapy for patients (pts) with anthracycline- and taxane-pretreated metastatic breast cancer (MBC).

S. Culine, P. Fumoleau, V. Diéras, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma

C. Jacquillat, D. Khayat, P. Fumoleau, 2004, Cancer Chemotherapy and Pharmacology.

The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment

P. Fumoleau, M. Fornier, 2012, The breast journal.

Adaptation and performance of an immuno-PCR assay for the quantification of Aviscumine in patient plasma samples.

C. Niemeyer, M. Adler, P. Fumoleau, 2005, Journal of pharmaceutical and biomedical analysis.

Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.

D. Lacombe, M. Campone, H. Zwierzina, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma

M. Namer, P. Fumoleau, P. Kerbrat, 1990, Cancer Chemotherapy and Pharmacology.

Phase II clinical evaluation of doxifluridine.

S. Schraub, J. Armand, P. Fumoleau, 1986, Cancer treatment reports.

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

J. Lemonnier, M. Lacroix-Triki, M. Campone, 2015, Future oncology.

Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer

L. Zitvogel, G. Kroemer, F. André, 2015, Autophagy.

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

K. Gelmon, J. Baselga, D. Miles, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer.

K. Gelmon, J. Baselga, J. Cortes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome

P. Gestraud, E. Berns, P. Hillemanns, 2019, EBioMedicine.

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

Denis Lacombe, Johan M Kros, R. Stupp, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.

R. Boidot, P. Fumoleau, F. Ghiringhelli, 2014, International journal of oncology.

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Tanja Cufer, Thierry Petit, Khalil Zaman, 2011, The Lancet. Oncology.

Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study

I. Ray-Coquard, P. Fumoleau, M. Sablin, 2015 .

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Alain Viari, Thomas Bachelot, Michael R. Stratton, 2016, Nature Communications.

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

W. Eiermann, M. Smylie, D. Slamon, 2004, Journal of the National Cancer Institute.

A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer

Mario Campone, H. Rugo, M. Campone, 2011, Clinical Cancer Research.

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).

T. Petit, F. Ringeisen, P. Fumoleau, 2010, Gynecologic oncology.

Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results.

J. Baselga, H. Burstein, P. Fumoleau, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.

P. Fumoleau, P. Fargeot, P. Kerbrat, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exosomes in cancer theranostic: Diamonds in the rough

C. Garrido, P. Fumoleau, R. Seigneuric, 2017, Cell adhesion & migration.

Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer.

A. Hammann, C. Garrido, A. de Thonel, 2016, Journal of the National Cancer Institute.

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

J. Baselga, A. Lluch, J. Tabernero, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast Cancer Blood Flow and Metabolism on Dual-Acquisition 18F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response

Alexandre Cochet, Olivier Humbert, François Brunotte, 2018, The Journal of Nuclear Medicine.

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

C. Coutant, N. Sevenet, C. Lepage, 2016, Oncotarget.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

H. Blanché, M. Mathieu, H. Bonnefoi, 2017, npj Breast Cancer.

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

G. Thomas, D. Cox, H. Blanché, 2016, Breast Cancer Research.

18F-FDG PET–Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer

P. Fumoleau, F. Brunotte, A. Cochet, 2016, The Journal of Nuclear Medicine.

HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy

C. Coutant, P. Fumoleau, F. Brunotte, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer

C. Coutant, P. Fumoleau, F. Brunotte, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.

C. Coutant, P. Fumoleau, F. Bonnetain, 2013, Breast.

Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes.

P. Fumoleau, F. Brunotte, L. Arnould, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of Breast Tumor Blood Flow with Dynamic First-Pass 18F-FDG PET/CT: Comparison with Angiogenesis Markers and Prognostic Factors

Alexandre Cochet, Olivier Humbert, François Brunotte, 2012, The Journal of Nuclear Medicine.

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

P. Fumoleau, C. Touzery, F. Brunotte, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.

G. Peters, J. Wanders, F. Caponigro, 2002, European journal of cancer.

Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene

C. Coutant, C. Lepage, T. Frebourg, 2013, European Journal of Human Genetics.

Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.

M. Buyse, M. Namer, F. Penault-Llorca, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.

P. Fumoleau, V. Diéras, P. Kerbrat, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.

M. van Glabbeke, M. Glabbeke, P. Fumoleau, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival

P. Fumoleau, S. Ladoire, L. Arnould, 2011, British Journal of Cancer.

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer

B. Asselain, L. Mauriac, P. Fumoleau, 2011, British Journal of Cancer.

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

J Bogaerts, J. Bergh, P. Malmström, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Presence of Foxp 3 expression in tumor cells predicts better survival in HER 2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy

B. Chauffert, P. Fumoleau, J. Vincent, 2010 .

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.

F. Penault-Llorca, R. Boidot, P. Fumoleau, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy

B. Chauffert, P. Fumoleau, J. Vincent, 2010, Breast Cancer Research and Treatment.

Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification

F. Penault-Llorca, P. Arveux, P. Fumoleau, 2007, Clinical Cancer Research.

Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.

J. Bonneterre, A. Monnier, P. Fumoleau, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

F. Penault-Llorca, P. Fumoleau, S. Ladoire, 2010, British Journal of Cancer.

[CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3].

C. Coutant, P. Fumoleau, V. Lorgis, 2016, Bulletin du cancer.

Identification of molecular apocrine breast tumours by microarray analysis

J. Bergh, D. Larsimont, M. Delorenzi, 2005, Breast Cancer Research.

The EORTC and drug development

D. Lacombe, G. Jayson, J. Verweij, 2002 .

Variations in Gene Expression and Response to Neoadjuvant Chemotherapy in Breast Carcinoma

F. Végran, R. Boidot, P. Fumoleau, 2009, Cancer investigation.

A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).

J. Bogaerts, L. Hayward, P. Fumoleau, 2014, Breast.

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

J. Bonneterre, P. Fumoleau, V. Diéras, 2012, British Journal of Cancer.

Prognostic factors of young women (≤ 35 years) with node positive breast cancer: possible influence on post-therapeutic follow-up.

J. Canon, P. Fumoleau, Anne-Laure Martin, 2013, Bulletin du cancer.

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

C. Coutant, P. Fumoleau, F. Ghiringhelli, 2011, The Journal of pathology.

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site

S. Rodenhuis, E. Barillot, A. Nicolas, 2020, British Journal of Cancer.

[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].

P. Fumoleau, F. Ghiringhelli, S. Ladoire, 2017, Annales de pathologie.

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

R. Epstein, M. Campone, I. Bondarenko, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

K. Gelmon, J. Baselga, J. Albanell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.

M. Campone, P. Fumoleau, S. Delaloge, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Leptomeningeal infiltration in esthesioneuroblastoma: report of two cases with poor prognosis.

P. Fumoleau, J. Louboutin, C. Maugard-Louboutin, 1994, European neurology.

Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.

P. Fumoleau, M. Giovannini, F. Rolland, 1997, Oral oncology.

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.

R. Stupp, M. J. van den Bent, A. Brandes, 2012, European journal of cancer.

Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer*

D. Lacombe, C. Punt, X. Paoletti, 2003, Investigational New Drugs.

Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.

D. Lacombe, M. Salzberg, X. Paoletti, 2003, European journal of cancer.

Traitements néo-adjuvants des cancers du sein HER2 positif

P. Fumoleau, C. Loustalot, L. Arnould, 2007 .

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.

M. Piccart, J. Wanders, J. Verweij, 2002, European journal of cancer.

Activity of gemcltabine in metastatic breast cancer (MBC) patients previously treated with anthracycline-containlng regimens

M. Espié, M. Namer, P. Fumoleau, 1997 .

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

W. Gradishar, A. Buzdar, K. Strasser-Weippl, 2015, Breast Cancer Research.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

M. Espié, D. Khayat, G. Romieu, 2013, The Lancet. Oncology.

Phase II study of cystemustine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group.

P. Fumoleau, P. Kerbrat, P. Chollet, 1993, European journal of cancer.

Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer

P. Fumoleau, Y. Cottin, C. Touzery, 2011, Breast Cancer Research and Treatment.

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.

S. Schraub, M. Namer, A. Monnier, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

T. Conroy, M. Ychou, F. Penault-Llorca, 2021, ESMO Open.

Role of positron emission tomography for the monitoring of response to therapy in breast cancer.

P. Fumoleau, F. Brunotte, A. Cochet, 2015, The oncologist.

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.

P. Fumoleau, V. Diéras, P. Kerbrat, 1996, British Journal of Cancer.

Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.

T. Delozier, P. Fumoleau, P. Hurteloup, 1995, Seminars in oncology.

Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.

M. Campone, P. Fumoleau, M. Bissery, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

UFT/leucovorin plus vinorelbine combination for advanced breast cancer.

J. Bonneterre, P. Fumoleau, P. Fargeot, 2000, Oncology.

UFT plus oral calcium folinate/vinorelbine for advanced breast cancer.

P. Fumoleau, P. Kerbrat, B. Laguerre, 1999, Oncology.

Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study.

P. Maingon, P. Arveux, P. Fumoleau, 2013, European journal of cancer care.

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

M. van Glabbeke, J. Armand, P. Fumoleau, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.

J. Douillard, P. Fumoleau, G. Ricolleau, 1984, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience.

M. Namer, J. Bonneterre, L. Mauriac, 1999, European journal of cancer.

Anthracycline as second line chemotherapy (CT) for metastatic breast cancer (MBC) patients previously treated with taxotere (TXT)

P. Fumoleau, A. Riva, C. Maugard, 1997 .

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

W. Gradishar, A. Buzdar, K. Strasser-Weippl, 2016, European journal of cancer.

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model

P. Fumoleau, F. Brunotte, J. Vrigneaud, 2018, Contrast media & molecular imaging.

[Clinical value of CA 15-3 for early detection of relapse in locally advanced breast cancer].

C. Coutant, P. Fumoleau, V. Lorgis, 2015, Bulletin du cancer.

Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.

M. Espié, D. Khayat, G. Romieu, 2015, European journal of cancer.

Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.

Chris Twelves, A. Ravaud, J. Wanders, 2005, European journal of cancer.

Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.

J. Soria, P. Fumoleau, A. Hollebecque, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors.

M. Espié, F. Reyal, B. Asselain, 2022, Reproductive Biomedicine Online.

Identi fi cation of Biomarkers Including 18 FDG-PET / CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

C. Coutant, P. Fumoleau, F. Brunotte, 2015 .

Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).

J. Armand, P. Fumoleau, P. Kerbrat, 1993, European journal of cancer.

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients

G. Thomas, D. Cox, H. Blanché, 2016, Oncotarget.

Roleof Positron Emission Tomography for theMonitoring of Response to Therapy in Breast Cancer

P. Fumoleau, F. Brunotte, A. Cochet, 2015 .

Phase II trial of pirarubicin in epidermoid carcinoma of the head and neck.

M. van Glabbeke, P. Hérait, J. Armand, 1992, European journal of cancer.

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

A. Vincent-Salomon, R. Rouzier, H. Brisse, 2020, Breast Cancer Research.

[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].

B. Chauffert, S. Taillibert, J. Honnorat, 2008, Revue neurologique.

Premenopausal Patients with Node-Positive Resectable Breast Cancer

S. Schraub, M. Namer, P. Fumoleau, 2012, Drugs.

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

J. Forbes, M. Buyse, G. Sauter, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy

M. Campone, P. Fumoleau, H. Cortés-Funes, 2006, British Journal of Cancer.

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

M. Espié, G. Romieu, I. Pauporté, 2018, Breast.

G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis

P. Fumoleau, G. Ricolleau, L. Campion, 2004, British Journal of Cancer.

Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: a pooled analysis of two randomised trials.

P. Fumoleau, Anne-Laure Martin, M. Spielmann, 2014, European journal of cancer.

Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours

R. Stupp, L. Nguyen, P. Fumoleau, 2007, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours.

E. Raymond, M. Campone, J. Armand, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program

L. Zelek, M. Namer, J. Pierga, 2004, Breast Cancer Research and Treatment.

Population pharmacokinetics and pharmacokinetic‐pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies

J. Wanders, E. Raymond, J. Schellens, 2002 .

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.

B. Weber, P. Fumoleau, L. Vanlemmens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity of ixabepilone, a novel epothilone b analog, across the breast cancer disease continuum

M. Piontek, E. Kubista, X. Pivot, 2008 .

Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.

P. Fumoleau, Anne-Laure Martin, F. Dalenc, 2012, Bulletin du cancer.

Original Paper EYcacy and Safety of Docetaxel (Taxotere 2 ) in Heavily Pretreated Advanced Breast Cancer Patients: the French Compassionate Use Programme Experience

M. Namer, J. Bonneterre, L. Mauriac, 1999 .

Original article DOI: 10.1093/annonc/mdg449 Phase

P. Fumoleau, V. Diéras, T. Bachelot, 2022 .

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

The vital role of education and information in patients receiving capecitabine (Xeloda).

P. Fumoleau, I. Chau, S. Legge, 2004, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.

M. Espié, M. Campone, T. Petit, 2006, Breast.

A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes

J. Bonneterre, M. Campone, G. Milano, 2012, Cancer Chemotherapy and Pharmacology.

Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.

T. Delozier, M. Namer, J. Bonneterre, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

J. Wanders, P. Fumoleau, J. Schellens, 2003, British Journal of Cancer.

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.

J. Wanders, M. Borner, P. Fumoleau, 2002, European journal of cancer.

Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies

D. Lacombe, J. Bonneterre, J. Pierga, 2005, Clinical Cancer Research.

Phase ICombining a P-Glycoprotein Inhibitor , MS 209 , in Combinationwith Docetaxel in Patients with AdvancedMalignancies

D. Lacombe, J. Bonneterre, J. Pierga, 2005 .

EORTC/GTO adjuvant chemotherapy program for primary Ewing's sarcoma: results at 5 years.

P. Fumoleau, C. Jasmin, B. Hoerni, 1978, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Pirarubicin in advanced breast cancer: a French cooperative phase II study.

T. Delozier, M. Namer, A. Monnier, 1990, European journal of cancer.

Postmenopausal Patients with Node-Positive Resectable Breast Cancer

M. Héry, M. Namer, A. Monnier, 2012, Drugs.

How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study.

A. Ravaud, L. Nguyen, P. Fumoleau, 2014, British journal of clinical pharmacology.

Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?

P. Fumoleau, C. Lévy, C Levy, 2005, Cancer treatment reviews.

RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.

D. Lacombe, C. Punt, S. Monfardini, 2004, European journal of cancer.

Role of positron emission tomography for the monitoring of response to therapy in breast cancer.

Alexandre Cochet, Olivier Humbert, Salim Kanoun, 2015, The Oncologist.

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST

P. Fumoleau, A. Bertaut, F. Brunotte, 2018, PloS one.

Future options with capecitabine (Xeloda) in (neo)adjuvant treatment of breast cancer.

D. Cameron, P. Fumoleau, 2004, Seminars in oncology.

Genetic alterations in early‐onset invasive breast carcinomas: Correlation of c‐erbB‐2 amplification detected by fluorescence In situ hybridization with p53 accumulation and tumor phenotype

P. Fumoleau, M. Heymann, M. Fiche, 1999, International journal of cancer.

Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.

M. Namer, J. Bonneterre, M. Campone, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction

A. Ravaud, P. Fumoleau, F. Saliba, 2013, Investigational New Drugs.

Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study.

Xavier Paoletti, Richard Sylvester, Patrick Schöffski, 2006, European journal of cancer.

Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.

M. Borner, J. Smyth, P. Fumoleau, 2001, European journal of cancer.

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

R. Epstein, M. Campone, I. Bondarenko, 2012 .

Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors

C. Ferrand, P. Fumoleau, G. Lizard, 2013, BMC Cancer.

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

D. Cox, H. Bonnefoi, G. Romieu, 2017, European journal of cancer.

Challenges in the implementation of trastuzumab biosimilars: an expert panel’s recommendations

J. Blay, X. Pivot, P. Fumoleau, 2015, Anti-cancer drugs.

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy

F. Végran, R. Boidot, P. Fumoleau, 2015, BMC Cancer.

Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis

R. Rouzier, F. Reyal, C. Coutant, 2016, Breast Cancer Research and Treatment.

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.

S. Mathoulin-Pélissier, X. Paoletti, B. Geoerger, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations

C. Coutant, P. Fumoleau, F. Brunotte, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

M. Campone, P. Fumoleau, N. Isambert, 2013, BMC Cancer.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

[Bone metastasis revealing a hepatoma. 13 cases].

P. Fumoleau, A. Prost, S. Cottin, 1981, Revue du rhumatisme et des maladies osteo-articulaires.

Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.

V. Quipourt, P. Fumoleau, F. Ghiringhelli, 2011, Clinical breast cancer.

ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL

M. Espié, M. Dowsett, R. Gelber, 2012 .

Efficacy and safety of docetaxel in clinical trials.

P. Fumoleau, 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Complementary roles of immunoscintigraphy and ultrasonography

P. Fumoleau, J. Chatal, M. Kremer, 2004, European Journal of Nuclear Medicine.

Phase II study of a new vinca alkaloid derivative, S12363, in advanced breast cancer

J. Bonneterre, P. Fumoleau, M. Marty, 2004, Cancer Chemotherapy and Pharmacology.

Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma

D. Dembélé, F. Végran, R. Boidot, 2009, British Journal of Cancer.

Pharmacokinetics of Tipifarnib After Oral and Intravenous Administration in Subjects With Advanced Cancer

M. Piccart-Gebhart, L. Dirix, Peter M. Porre, 2006, Journal of clinical pharmacology.

Docetaxel and cisplatin in head and neck cancer.

J. Wanders, J. Verweij, P. Fumoleau, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group.

P. Fumoleau, P. Kerbrat, P. Chollet, 1998, European journal of cancer.

Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) results

M. Namer, J. Bonneterre, A. Monnier, 2005 .

Abstract P6-11-08: A multicenter, open-label Ph IB/II study of BEZ235, an oral dual PI3K/mTOR inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer

M. Campone, A. Urruticoechea, J. Beck, 2012 .

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.

M. Espié, D. Khayat, G. Romieu, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

G. Thomas, D. Cox, H. Blanché, 2017, npj Breast Cancer.

Preliminary phase II trial of oxaliplatin (L-OHP) in malignant astrocytomas

P. Fumoleau, S. Bourdin, Y. Lajat, 1993 .

938 Docetaxel (D) in combination with vinorelbine (V) as first line CT in PTS with MBC: Phase I dose finding study

P. Fumoleau, A. Riva, G. Perrocheau, 1995 .

Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure.

M. Campone, P. Ruff, P. Fumoleau, 2004, Journal of Clinical Oncology.

Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): Pharmacokinetic results

A. Ravaud, P. Fumoleau, F. Saliba, 2007 .

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10min infusion every 3 weeks in patients with advanced solid tumours

E. Raymond, M. Campone, J. Armand, 2002 .

Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix.

M. van Glabbeke, P. Fumoleau, V. Diéras, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.

P. Fumoleau, P. Kerbrat, C. Lhommé, 1996, Seminars in oncology.

Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV + docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC]).

R. Greil, S. Barni, D. Miles, 2009 .

Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.

P. Fumoleau, J. Misset, G. Mathé, 1986, Drugs under experimental and clinical research.

Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)

S. Aamdal, J. Wanders, J. Verweij, 2000, Cancer Chemotherapy and Pharmacology.

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.

A. Monnier, P. Fumoleau, N. Colombo, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis.

M. Piccart, J. Bogaerts, H. Bonnefoi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of patients with liver metastases

P. Fumoleau, 1996, Anti-Cancer Drugs.

Phase II Trials of Tetrahydropyranyl‐Adriamycin (Pirarubicin) on Renal and Colon Carcinoma, Melanoma, and Soft Tissue Sarcoma

P. Hérait, J. Armand, P. Fumoleau, 1993, American journal of clinical oncology.

Breast Cancer Research and Treatment 2001 Reviewers

D. Berry, L. Holmberg, D. Alberts, 2004, Breast Cancer Research and Treatment.

Epirubicin‐Docetaxel Combination in First‐Line Chemotherapy for Patients With Metastatic Breast Cancer: Final Results of a Dose‐Finding and Efficacy Study

T. Delozier, P. Viens, P. Fumoleau, 2001, American journal of clinical oncology.

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

S. Shak, F. Baehner, F. Penault-Llorca, 2018, BMC Cancer.

Identification of molecular apocrine breast tumours by microarray analysis

D. Larsimont, M. Delorenzi, P. Farmer, 2005 .

Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching.

P. Maingon, P. Arveux, P. Fumoleau, 2012, European journal of cancer.

High quality gene expression microarray data from a multicentre prospective trial: results of the first microarray analysis in the EORTC 10994/BIG 00–01 study

J. Bergh, M. Piccart, P. Farmer, 2004 .

Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).

J. Wanders, E. Raymond, J. Beijnen, 2002, British journal of clinical pharmacology.

Benefit of neoadjuvant capecitabine + epirubicin + cyclophosphamide (CEX) versus 5-FU + epirubicin + cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T)

F. Penault-Llorca, G. Milano, P. Fumoleau, 2008 .

Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

P. Fumoleau, N. Isambert, G. Freyer, 2012, Clinical Cancer Research.

Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

GEP01: A phase I study of lapatinib (L) and vinorelbine (VNR) in HER2 overexpressing (HER2+) locally advanced or metastatic breast cancer (LAMBC) patients (pts): A FNCLCC Group of early phase trials study.

J. Bonneterre, P. Fumoleau, V. Diéras, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.

P. Fumoleau, A. Floquet, C. Tourneau, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.